Literature DB >> 956374

A role for adenosine deaminase in human monocyte maturation.

D Fischer, M B Van der Weyden, R Snyderman, W N Kelley.   

Abstract

The occurrence of a deficiency of adenosine deaminase (ADA) activity in some patients with severe combined immunodeficiency suggests a possible relationship between the activity of ADA and the aberration of the immune system. To help delineate the function of ADA in the immune response we have examined its role in monocyte maturation. When incubated in vitro, peripheral blood monocytes transformed, within 3 days, to macrophagea as assessed by phase-contrast microscopy and an increase in the specific activity of the lysosomal enzyme acid phosphatase. The specific activity of ADA increased as much as ninefold, reaching a peak after the 1st day in culture, while the activities of other enzymes involved in the purine salvage pathway were not altered. Sucrose density ultracentrifugation of extracts prepared immediately after the isolation of monocytes revealed the presence of two forms of ADA with molecular weights of approximately 30,000 and 110,000. The increase in ADA specific activity during monocyte cultivation correlated with an increase in the activity of the smaller molecular species. A specific inhibitor ADA, erythro-9-(2-hydroxy-3-nonyl) adenine, prevented the increase in acid phosphatase activity, as well as the morphological changes associated with the monocyte maturation. These data suggest a role for ADA in monocyte to macrophage maturation. In view of the central role of macrophages in immune function, this observation may relate to the association of combined immunodeficiency and a deficiency of this enzyme.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 956374      PMCID: PMC333195          DOI: 10.1172/JCI108484

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  ACID PHOSPHATASE ACTIVITY IN NORMAL HUMAN BLOOD AND BONE MARROW CELLS AS DEMONSTRATED BY THE AZO DYE METHOD.

Authors:  L ROZENSZAJN; G MARSHAK; P EFRATI
Journal:  Acta Haematol       Date:  1963-11       Impact factor: 2.195

2.  The inflammatory response.

Authors:  W G SPECTOR; D A WILLOUGHBY
Journal:  Bacteriol Rev       Date:  1963-06

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  Adenosine-deaminase deficiency and combined immunodeficiency syndrome.

Authors:  J Dissing; B Knudsen
Journal:  Lancet       Date:  1972-12-16       Impact factor: 79.321

5.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity.

Authors:  E R Giblett; J E Anderson; F Cohen; B Pollara; H J Meuwissen
Journal:  Lancet       Date:  1972-11-18       Impact factor: 79.321

Review 6.  The regulatory role of macrophages in antigenic stimulation.

Authors:  E R Unanue
Journal:  Adv Immunol       Date:  1972       Impact factor: 3.543

7.  Some properties of partially purified mammalian adenosine kinase.

Authors:  B Lindberg; H Klenow; K Hansen
Journal:  J Biol Chem       Date:  1967-02-10       Impact factor: 5.157

8.  A specific enzyme defect in gout associated with overproduction of uric acid.

Authors:  W N Kelley; F M Rosenbloom; J F Henderson; J E Seegmiller
Journal:  Proc Natl Acad Sci U S A       Date:  1967-06       Impact factor: 11.205

9.  Monocyte kinetic studies in normal and disease states.

Authors:  G Meuret; G Hoffmann
Journal:  Br J Haematol       Date:  1973-03       Impact factor: 6.998

10.  Enzyme inhibitors. 26. Bridging hydrophobic and hydrophilic regions on adenosine deaminase with some 9-(2-hydroxy-3-alkyl)adenines.

Authors:  H J Schaeffer; C F Schwender
Journal:  J Med Chem       Date:  1974-01       Impact factor: 7.446

View more
  36 in total

1.  Elevated adenosine deaminase levels in celiac disease.

Authors:  Basak Cakal; Yavuz Beyazit; Seyfettin Koklu; Erdem Akbal; Ibrahim Biyikoglu; Gulsen Yilmaz
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

2.  Structural differences between plasma-membrane 5'-nucleotidase in different cell types as evidenced by antibodies.

Authors:  J Harb; K Meflah; S Bernard
Journal:  Biochem J       Date:  1985-12-15       Impact factor: 3.857

Review 3.  Potential for developing purinergic drugs for gastrointestinal diseases.

Authors:  Fernando Ochoa-Cortes; Andromeda Liñán-Rico; Kenneth A Jacobson; Fievos L Christofi
Journal:  Inflamm Bowel Dis       Date:  2014-07       Impact factor: 5.325

4.  Abortive and productive infections of human mononuclear phagocytes by type I herpes simplex virus.

Authors:  C A Daniels; E S Kleinerman; R Snyderman
Journal:  Am J Pathol       Date:  1978-04       Impact factor: 4.307

5.  Immunomorphological localization of adenosine deaminase in rat tissues during ontogeny.

Authors:  B E Chechik; S Sengupta; T Hibi; B Fernandes
Journal:  Histochem J       Date:  1985-02

6.  Purine excretion by mouse peritoneal macrophages lacking adenosine deaminase activity.

Authors:  T S Chan
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

7.  Pleural fluid interferon-gamma and adenosine deaminase levels in tuberculosis pleural effusion: a cost-effectiveness analysis.

Authors:  S K Sharma; Amit Banga
Journal:  J Clin Lab Anal       Date:  2005       Impact factor: 2.352

8.  Tissue factor activity. A marker of alveolar macrophage maturation in rabbits. Effects of granulomatous pneumonitis.

Authors:  H Rothberger; M P McGee; T K Lee
Journal:  J Clin Invest       Date:  1984-06       Impact factor: 14.808

9.  Adenosine A2 receptors on human monocytes modulate C2 production.

Authors:  D Lappin; K Whaley
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

10.  Regulation of adenosine receptor subtypes during cultivation of human monocytes: role of receptors in preventing lipopolysaccharide-triggered respiratory burst.

Authors:  Andrea Thiele; Romy Kronstein; Anne Wetzel; Anja Gerth; Karen Nieber; Sunna Hauschildt
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.